Tag: M&A
-

Viatris to Acquire Pacira for $1.65B in Non-Opioid Pain Push
Viatris agreed to acquire Pacira BioSciences for $1.65 billion, adding Exparel, Zilretta and an established U.S. specialty platform. The deal advances Viatris’ shift toward innovative medicines but also introduces patent, generic competition and integration risks.
-

Curium to Acquire Lantheus in an $8 Billion Radiopharma Deal
Curium’s acquisition of Lantheus could create a global radiopharma leader by combining isotope manufacturing, diagnostics, and commercial scale.
-

Eli Lilly Strikes $475 M Gene Therapy Deal with MeiraGTx for Rare Retinal Disease
Eli Lilly’s $475 million acquisition of MeiraGTx marks a bold step into next-generation gene therapies targeting rare retinal diseases. Despite challenges in the gene therapy market, the move reflects growing optimism about using advanced genetic tools to improve the lives of patients with rare inherited disorders.
-

Pfizer Lands Metsera Acquisition After Novo Nordisk Bows Out of $10 B Bidding War
Pfizer’s acquisition of Metsera secures a high-potential obesity-drug pipeline — but because Metsera’s assets are early-stage, the deal carries meaningful regulatory and execution risk.
-

The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.